[1] Werner RN et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratoses - International League of Derma- tological Societies in cooperation with the European dermatology forum – shortversion. JEADV 2015;29:2069-2079.

[2] Reygagne P et al. Au-delà des keratoses actiniques, le champ de cancérisation cutané.Ann DermatolVenerol 2018;145:587-592.

[3] Cribier B. Kératoses actiniques: diagnostic anatomoclinique. Ann DermatolVenerol 2019;146:IIS10-IIS15.

[4] Carcinome épidermoïde cutané (carcinome spinocellulaire): recom- mandations de pratique cliniquepour la prise en charge diagnostique et thérapeutique. Argumentaire Mai 2009. Ann Dermatol Venerol 2009; 136:S189-S242.

[5] Stockfleth E. The importance of treating the field in actinic keratosis. JEADV 2017;31(Suppl 2):8-11.

[6] Zalaudek, I et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasivesquamous cell carcinoma:A progression model. JAAD 2012;66(4):589-597.

[7] Zalaudek I et al. Dermoscopy of facial nonpigmented actinic keratosis. Brit J Dermatol2006;155(5):951-956.

[8] Stockfleth E. Actinic keratosis and filed cancerisation. Eur J Der- matol 2011;21(Suppl 1):3-12.

[9] Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. JEADV 2017;31(Suppl 2):5-7.



[10] Cunningham T. Randomized trial of calcipotriol combined with5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest 2017;127(1):106-116.